These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 19060513)
1. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Molina R; Auge JM; Escudero JM; Marrades R; Viñolas N; Carcereny E; Ramirez J; Filella X Tumour Biol; 2008; 29(6):371-80. PubMed ID: 19060513 [TBL] [Abstract][Full Text] [Related]
2. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
3. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum tumor markers in patients with lung cancer. Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM Respiration; 2002; 69(1):25-9. PubMed ID: 11844959 [TBL] [Abstract][Full Text] [Related]
5. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
6. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229 [TBL] [Abstract][Full Text] [Related]
7. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
9. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China. Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515 [TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Molina R; Agusti C; Mañe JM; Filella X; Jo J; Joseph J; Giménez N; Estapé J; Ballesta AM Int J Biol Markers; 1994; 9(2):96-101. PubMed ID: 7523548 [TBL] [Abstract][Full Text] [Related]
12. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Molina R; Filella X; Augé JM; Fuentes R; Bover I; Rifa J; Moreno V; Canals E; Viñolas N; Marquez A; Barreiro E; Borras J; Viladiu P Tumour Biol; 2003; 24(4):209-18. PubMed ID: 14654716 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Seemann MD; Beinert T; Fürst H; Fink U Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925 [TBL] [Abstract][Full Text] [Related]
14. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Ebert W; Hoppe M; Muley T; Drings P Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552 [TBL] [Abstract][Full Text] [Related]
15. The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. Wang P; Piao Y; Zhang X; Li W; Hao X Cancer Biomark; 2013; 13(2):123-30. PubMed ID: 23838141 [TBL] [Abstract][Full Text] [Related]
16. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
18. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
19. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]